Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX: Plasma Oxytocin in Response to Oral Estradiol Valerate and Ethinylestradiol
NCT07361263Recruiting
- Sponsor
- University Hospital Basel
- Start
- Jan 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of estradiol valerate and ethinyl estradiol in Oxytocin deficiency (2 arms), sponsored by University Hospital Basel. Primary endpoints: Relative Change in Plasma Oxytocin at 300 minutes and Relative Change in Neurophysin-1 at 300 minutes. Started Jan 2026; status: recruiting.
02
Drugs
estradiol valerateethinyl estradiol
03
Conditions
Oxytocin deficiency
Beyond the preview
Go deeper on NCT07361263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361263.